Tag: Orgovyx

Approved by the FDA in December 2020, Orgovyx (relugolix) marked a significant milestone as the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for advanced prostate cancer. The initial manufacturer and commercializing partner for Orgovyx was Myovant Sciences, Inc., working in collaboration with Pfizer, Inc.

As of a 2021 clinical trial, the oral medication relugolix (Orgovyx) was shown to be more effective at suppressing testosterone levels in men with advanced prostate cancer compared to the long-used injectable leuprolide (Lupron). Understanding what is the difference between Orgovyx and Lupron is crucial for patients and healthcare providers to make informed decisions regarding treatment for this condition.

Clinical trial data shows that 99% of men on Orgovyx had a rapid drop in testosterone within 15 days. Understanding this response helps track progress and shows how do you know if Orgovyx is working against advanced prostate cancer.

In 2022, an estimated 24,600 men in Canada were diagnosed with prostate cancer, making it the most common cancer among Canadian men [1.4.5]. For those with advanced disease, a key question is: **how long can you stay on Orgovyx?** This is determined by efficacy and tolerability.

In clinical trials, 55% of patients regained baseline testosterone levels within 12 weeks of discontinuing Orgovyx, showing a faster recovery compared to injectable therapies. Patients undergoing treatment for advanced prostate cancer often ask, 'how long do the side effects of Orgovyx last?' as they manage symptoms tied to hormone suppression.

According to the National Cancer Institute, Orgovyx, also known by its generic name relugolix, is a drug used to treat adults with advanced prostate cancer. It represents the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for this condition, offering a new and convenient treatment approach.